About the Authors

Kevin G. McLure

kevin@resverlogix.com

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Emily M. Gesner

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Laura Tsujikawa

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Olesya A. Kharenko

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Sarah Attwell

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Eric Campeau

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Sylwia Wasiak

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Adam Stein

Current address: Cayman Chemical, Ann Arbor, Michigan, United States of America

Affiliation Xtal BioStructures Inc., Natick, Maryland, United States of America

Andre White

Affiliation Xtal BioStructures Inc., Natick, Maryland, United States of America

Eric Fontano

Affiliation Xtal BioStructures Inc., Natick, Maryland, United States of America

Robert K. Suto

Affiliation Xtal BioStructures Inc., Natick, Maryland, United States of America

Norman C. W. Wong

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Gregory S. Wagner

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Henrik C. Hansen

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Peter R. Young

Affiliation Resverlogix Corp., Calgary, Alberta, Canada, or San Francisco, California, United States of America

Competing Interests

Authors affiliated with Resverlogix receive salary from and stock options in Resverlogix. Authors affiliated with Xtal BioStructures were compensated by Resverlogix for work performed. HCH is an inventor on RVX-208 composition of matter patents. KGM and PRY are inventors on patent applications for method of use of Resverlogix BET inhibitors for Treatment of Diseases by Epigenetic Regulation. The relevant United States patent is United States 8,053,440 with HCH as inventor. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: KGM EMG LT OAK SA EC RKS PRY. Performed the experiments: EMG LT OAK SA EC SW AS EF. Analyzed the data: KGM EMG LT OAK SA EC SW AS AW EF RKS NCW GSW PRY. Contributed reagents/materials/analysis tools: HCH. Wrote the paper: PRY KGM RKS.